Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

To explore the characteristics of senescent melanoma cells induced by vemurafenib or cisplatin, melanoma A375 cells were treated with vemurafenib and cisplatin, respectively. The senescent phenotypes were verified by ß-gal staining, EdU assay, cell morphology and the senescence-related pathways. RNA-seq was performed to explore the differentially expressed genes in the senescent cells induced by vemurafenib or cisplatin. Overall design: Melanoma A375 cells were treated with vemurafenib (10 µM) for 3 days or with cisplatin (2 µM) for 1 day and then returned to normal culture conditions. At day 7 after the treatment, A375 cells were collected and used for RNA-seq and other detections. Normal cultured A375 cells were simultaneously collected and acted as negative control.